ULBI — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-05-08

• Consolidated revenues of $47,445 for the three-month period ended March 31, 2026, decreased by $3,301 or 6.5%, over $50,746 for the three-month period ended March 31, 2025, reflecting a 5.5% decline in commercial sales and an 8.2% decline in government/defense sales.

• Operating expenses were $10,325 for the three-month period ending March 31, 2026, compared to $9,346 for the three-month period ended March 31, 2025, reflecting an increase in new product development costs related to continued investment in our product offering and certain one-time, non-recurring co…

• Net (loss) income attributable to Ultralife Corporation was ($451), or ($0.03) per share – basic and diluted, for the three-month period ended March 31, 2026, compared to $1,865, or $0.11 per share – basic and diluted, for the three-month period ended March 31, 2025.

• Adjusted EBITDA, defined as net (loss) income attributable to Ultralife Corporation before net interest expense, (benefit) provision for income taxes, depreciation and amortization, and stock-based compensation expense, plus/minus expenses/income that we do not consider reflective of our ongoing ope…

• We remain intently focused on improving manufacturing efficiencies at our Newark, NY facility, particularly as we ramp up production of new products, in order to increase the gross margin of Battery & Energy Products, and on driving Communications Systems orders. These improvements, along with execu…

Text removed vs the prior filing · source: 10-Q · 2025-11-17

• Consolidated revenues of $43,371 for the three-month period ended September 30, 2025, increased by $7,677 or 21.5%, over $35,694 for the three-month period ended September 30, 2024, reflecting the inclusion of Electrochem sales of $6,797, and an increase in government/defense of 16.4%, partially off…

• Operating expenses were $10,570 for the three-month period ending September 30, 2025, compared to $8,171 for the three-month period ended September 30, 2024, reflecting the inclusion of Electrochem’s results and certain one-time, non-recurring costs, including a provision for the estimated costs of …

• Other expense for the third quarter of 2025 was $800 compared to $158 for the year-earlier quarter. The increased expense for the 2025 period primarily reflects the increase in interest expense relating to our acquisition of Electrochem on October 31, 2024.

• Net (loss) income attributable to Ultralife Corporation was ($1,220), or ($0.07) per share – basic and diluted, for the three-month period ended September 30, 2025, compared to $258, or $0.02 per share – basic and diluted, for the three-month period ended September 30, 2024.

• Adjusted EBITDA, defined as net income attributable to Ultralife Corporation before net interest expense, provision (benefit) for income taxes, depreciation and amortization, and stock-based compensation expense, plus/minus expenses/income that we do not consider reflective of our ongoing operations…

Text added vs the prior filing · source: 10-Q · 2026-05-08

• Material Weakness in Internal Control over Financial Reporting

• Management conducted an evaluation of the effectiveness of our internal control over financial reporting as of December 31, 2025, using the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) in Internal Control - Integrated Framework (2013). Based on …

• A material weakness has been identified because remediation efforts initiated during the year ended December 31, 2025 relating to the material weakness identified during the year ended December 31, 2024 attributable to the need for additional personnel to provide a full complement of accounting and …

• Over the course of 2025, management implemented a remediation plan designed to address the material weakness identified during the year ended December 31, 2024, attributable to the need for additional personnel to provide a full complement of accounting and reporting expertise commensurate with the …

• During the first quarter of 2026 and through the date of this Quarterly Report on Form 10-Q, management continues to develop and is actively implementing corrective actions to remediate the identified ITGC deficiencies. The Company is conducting a comprehensive risk-based evaluation of user access t…

Text removed vs the prior filing · source: 10-Q · 2025-11-17

• Management conducted an evaluation of the effectiveness of our internal control over financial reporting as of December 31, 2024, using the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) in Internal Control - Integrated Framework (2013). Based on …

• Management has taken the necessary steps to remediate our identified material weakness. The Company has significantly strengthened its finance and accounting team by adding a new oversight role and hiring additional highly experienced personnel including certified public accountants to augment the e…

• Remediation will be deemed complete once our corrective actions are fully implemented and further evaluation is performed, including testing, to conclude that our internal control over financial reporting is effective.

• To continue our improvement in internal controls over financial reporting (as defined in Securities Exchange Act Rule 13a-15(f)) during the third quarter, we completed the re-organization of our Corporate Accounting organization and have appointed a Chief Accounting Officer, backfilled our Corporate…